Mufrosyn® is a form of cysteamine (inhaled) being developed by NovaBiotics to treat non-cystic fibrosis bronchiectasis and COPD (conditions which often overlap).
Chronic lower respiratory tract disease affects tens of millions of individuals globally. Not only do these conditions impact air flow and lung function and therefore quality of life, but diseases such as chronic obstructive pulmonary disease (COPD) are a major cause of mortality - COPD being the third leading cause of death in the U.S.
The anti-inflammatory and mucolytic (plus antimicrobial) properties of cysteamine are a potent and unique combination in addressing chronic respiratory conditions.
AB21 9TR, UK
Tel:+44 (0)1224 711377
One Boston Place,